Abstract

Provided herein are novel lipase inhibitors and methods for using the same to treat inflammation, multisystem organ failure, necrotic pancreatic acinar cell death, acute pancreatitis, sepsis (e.g., culture negative sepsis), burns, and acne. For example, provided herein are two novel lipase inhibitors useful in the methods described herein: Provided herein are novel lipase inhibitors and methods for using the same to treat inflammation, multisystem organ failure, necrotic pancreatic acinar cell death, acute pancreatitis, sepsis (e.g., culture negative sepsis), burns, and acne. For example, provided herein are two novel lipase inhibitors useful in the methods described herein: Provided herein are novel lipase inhibitors and methods for using the same to treat inflammation, multisystem organ failure, necrotic pancreatic acinar cell death, acute pancreatitis, sepsis (e.g., culture negative sepsis), burns, and acne. For example, provided herein are two novel lipase inhibitors useful in the methods described herein: or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• C07D 205/08 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
• A61K 31/365 - Lactones
• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• A61P 3/04 - AnorexiantsAntiobesity agents

Abstract

This document relates to methods and materials involved in treating cancer. For example, methods and materials for using chimeric antigen receptor (CAR) T cells having reduced levels of an interleukin (IL) 4 polypeptide, having reduced levels of a transcription factor 7 (TCF7) polypeptide, having reduced levels of a protein tyrosine phosphatase non-receptor type 2 (PTPN2) polypeptide, and/or having reduced levels of a protein tyrosine phosphatase non-receptor type 3 (PTPN3) polypeptide are provided. Methods and materials for using such CAR T cells in an adoptive cell therapy (e.g., a CAR T cell therapy) to treat a mammal (e.g., a human) having cancer also are provided

IPC Classes  ?

• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61P 35/00 - Antineoplastic agents
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/54 - Interleukins [IL]
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes

Goods & Services

Printed educational materials in the field of nursing and medical care

Goods & Services

Downloadable printable educational materials in the field of nursing and medical care

Goods & Services

Medical services; Nursing services

Goods & Services

Education services, namely, providing classes, seminars, workshops, and conferences in the field of nursing and medical care; Publication of on-line materials in the field of nursing and medical care

Abstract

An apparatus and method for detecting a level of cardiovascular disease. The apparatus includes at least a processor and a memory communicatively connected to the at least a processor, wherein the memory contains instructions configuring the at least a processor to: receive a plurality of voltage-time data, generate at least a feature vector from the voltage-time data by at least a feature model, input the at least feature vector into a cardiovascular classification model, generate at least a disease indication in a subject using the classification model, wherein the disease indication comprises a level of myocarditis, and display the at least a disease indication.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/341 - Vectorcardiography [VCG]
• A61B 5/346 - Analysis of electrocardiograms
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records

Abstract

Methods and materials for treating mammals having cardiovascular and/or metabolic disease are provided herein. For example, methods and materials for treating mammals having cardiovascular and/or metabolic disease by administering (a) an analog of a natriuretic peptide (NP), such as atrial natriuretic peptide (ANP) or dendroaspis natriuretic peptide (DNP), and (b) a glucagon-like peptide-1 (GLP-1) receptor / glucose-dependent insulinotropic polypeptide (GIP) receptor agonist are provided herein. The NP analogs used in the methods provided herein can be less than 20 amino acids in length and, in some cases, can have one or more variations in their ring portion (as compared to wild type ANP or DNP) that affect the potency of the analog in activating the particulate guanylyl cyclase (GC-A) receptor.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/605 - Glucagons
• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61K 38/26 - Glucagons
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

Embodiments herein relate to dispersion catheter systems and related methods. In an embodiment, a dispersion catheter system for delivering injectates to small diameter vessels of a patient is included having a dispersion catheter shaft defining a lumen and a dispersion catheter tip in fluid communication with the lumen of the dispersion catheter shaft. The dispersion catheter system can also include a fluid dispersal cap (204), wherein the fluid dispersal cap (204) is configured to be disposed within a path of fluid flow coming from the dispersion catheter tip. The fluid dispersal cap (204) can have one or more internal flow conduits, side flow ports (308), side flow channels, and/or outflow ports. Other embodiments are also included herein.

IPC Classes  ?

• A61M 25/00 - CathetersHollow probes

Abstract

Embodiments herein relate to dispersion catheter systems and related methods. In an embodiment, a dispersion catheter system for delivering injectates to small diameter vessels of a patient is included having a dispersion catheter shaft defining a lumen and a dispersion catheter tip in fluid communication with the lumen of the dispersion catheter shaft. The dispersion catheter system can also include a fluid dispersal cap, wherein the fluid dispersal cap is configured to be disposed within a path of fluid flow coming from the dispersion catheter tip. The fluid dispersal cap can have one or more internal flow conduits, side flow ports, side flow channels, and/or outflow ports. Other embodiments are also included herein.

IPC Classes  ?

• A61M 25/00 - CathetersHollow probes
• A61M 25/09 - Guide wires

Abstract

This document relates to devices and methods for joining a suture device with a medical imaging device. For example, this document relates to devices and methods for joining a suture device with an endoscopic ultrasound (EUS) device so that a clinician can perform a medical procedure with the suture device under direct visualization from the EUS device.

IPC Classes  ?

• A61B 8/12 - Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters
• A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials

Abstract

This document provides methods and materials for treating a mammal having cancer. For example, T cells (e.g., chimeric antigen receptor (CAR) T cells) engineered to express an antigen receptor (e.g., a CAR) that can target a thyroid stimulating hormone receptor (TSHR) polypeptide are provided. In some cases, T cells provided herein can be administered to a mammal having cancer to treat the mammal. For example, one or more T cells expressing (e.g., engineered to express) an antigen receptor (e.g., a CAR) that can target a TSHR polypeptide can be administered (e.g., in an adoptive cell therapy such as a CAR T cell therapy) to a mammal (e.g., a human) having cancer (e.g., thyroid cancer) to treat the mammal.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/42 - Cancer antigens
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Disclosed herein are systems, devices, and methods for accessing a subdural space. In some embodiments, an apparatus may comprise a shaft configured to be slidably disposed within a lumen of a catheter. The shaft may be configured to be advanced distally from a distal end of the catheter and into a blood vessel of a subject. The shaft may include a perforating tip including an energy element configured to generate radiofrequency energy to form an opening through a wall of the blood vessel and dura of the subject and into an extravascular space of the subject. A curved section may be configured to be radially constrained within the lumen of the catheter and to curve toward the wall of the blood vessel and the dura upon exiting the lumen of the catheter such that the energy element is positioned to form the opening.

IPC Classes  ?

• A61B 18/14 - Probes or electrodes therefor
• A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
• A61B 17/32 - Surgical cutting instruments
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
• A61M 25/00 - CathetersHollow probes
• A61M 27/00 - Drainage appliances for wounds, or the like

Abstract

In some embodiments, a machine learning model may be accessed and used to generate a likelihood score related to a condition. In some embodiments, pre-computed vectors may be derived from a training dataset used to build the machine learning model, and the pre-computed vectors may be used to generate processed data from target data derived from a target sample. The machine learning model may then be used on the processed data to generate the likelihood score related to the condition. As an example, subsets of the training dataset may be randomly selected, and the pre-computed vectors may be derived from the randomly-selected subsets of the training dataset. The pre-computed vectors may be applied to the target data to generate the processed data. In one use case, for example, the target data may be normalized using the pre-computed vectors.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G06N 5/01 - Dynamic search techniquesHeuristicsDynamic treesBranch-and-bound

Abstract

Provided herein is technology for breast cancer screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of breast cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/6811 - Selection methods for production or design of target specific oligonucleotides or binding molecules
• C12Q 1/682 - Signal amplification
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
• C12Q 1/6853 - Nucleic acid amplification reactions using modified primers or templates
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

This document relates to methods and materials for treating mammals having autosomal dominant polycystic kidney disease (ADPKD). For example, this document provides methods and materials for correcting a point mutation in the PKD1 gene that is associated with ADPKD.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• C12N 15/86 - Viral vectors

Abstract

This document relates to methods and materials involved in assessing and/or treating mammals having a caveolinopathy disease (e.g., immune-mediated rippling muscle disease (iRMD)). For example, methods and materials for detecting the presence of an autoantibody specific for a caveolae-associated protein 4 (cavin-4) polypeptide to identify a mammal as having iRMD as well as methods for treating a mammal identified having iRMD are provided. In some cases, cavin-4 polypeptides (and/or fragments thereof and/or variants thereof) can be used to detect the presence or absence of anti-cavin-4 polypeptide autoantibodies indicative of iRMD.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease

Abstract

Mechanical properties of a tissue in a subject are estimated from phase velocity dispersion curve data that are corrected for unreliable low frequency phase velocity estimates. Elastography data are acquired from a region in a subject in which mechanical waves are propagating. The elastography data are acquired with a medical imaging system. Phase velocity dispersion curve data and group velocity data are generated from the elastography data. Corrected phase velocity dispersion curve data are then generated by correcting low frequency phase velocity values in the phase velocity dispersion curve data using the group velocity data. Mechanical property data are then generated from the corrected phase velocity dispersion curve data.

IPC Classes  ?

• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• G01S 7/52 - Details of systems according to groups , , of systems according to group
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

This document relates to methods and materials for treating cancer. For example, this document provides chimeric vesiculoviruses (e.g., chimeric vesicular stomatitis viruses (VSVs)) and methods for using such chimeric vesiculoviruses as an oncolytic agent (e.g., to treat cancer).

IPC Classes  ?

• A61K 35/766 - Rhabdovirus, e.g. vesicular stomatitis virus
• A61P 35/00 - Antineoplastic agents
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/86 - Viral vectors
• A61K 39/12 - Viral antigens

Abstract

Phase-sensitive water-fat separation magnetic resonance imaging (MRI) includes acquiring k-space data with an MRI system. The k-space data are acquired at echo times (TEs) at which water spins and fat spins are at least partially out-of-phase with each other. One or more TE images are reconstructed from the k-space data. A background phase is estimated from the TE image(s). One or more phase-corrected images are generated by performing phase correction on the TE image(s) using the background phase. Separated water images and fat images are generated from the phase-corrected image(s). At least one set of the water images or the fat images are then output.

IPC Classes  ?

• G01R 33/48 - NMR imaging systems
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
• G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities
• G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography

Abstract

Methods and materials for using purified exosome product (PEP) as a carrier in delivery of therapeutic agents to mammals are provided herein. For example, methods and materials for using drug-carrying PEP in the administration (e.g., by convection-enhanced delivery) of one or more drugs to a mammal are provided herein.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 5/07 - Animal cells or tissues
• A61K 8/14 - Liposomes

Abstract

A microfluidic device includes a channel layer configured for flow of a fluid medium; and a plurality of microwells in fluid communication with the channel layer, the plurality of microwells each comprising a well depth and a well diameter that prevents fluid flow of the fluid medium into the plurality of microwells during circulation of the fluid medium in the channel layer.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 33/533 - Production of labelled immunochemicals with fluorescent label

Abstract

Systems and methods include a component of a bone implant that includes a patient specific bone contacting surface and, optionally, at least one protrusion adjacent to or extending from the patient specific bone contacting surface. The at least one protrusion is configured for engaging a bone preparation in the bone. To prepare the bone for receiving the component, one or more cutting tool templates may be used. The one or more cutting tool templates may be fabricated to have a patient specific bone contacting surface that engages the bone that is to receive the implant component. A cutting tool is engaged in one or more of one or more slots defined by the cutting tool template(s) to remove surface portions of the bone to create the bone preparation for engaging the protrusion. The patient specific bone contacting surface of the component engages the bone.

IPC Classes  ?

• A61B 17/17 - Guides for drills
• A61B 17/56 - Surgical instruments or methods for treatment of bones or jointsDevices specially adapted therefor
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
• B33Y 50/00 - Data acquisition or data processing for additive manufacturing
• B33Y 80/00 - Products made by additive manufacturing

Abstract

The present disclosure provides materials and methods for assessing and/or treating subjects having prostate cancer. In some embodiments, materials and methods for assessing a subject's tumor burden using a liquid biomarker, tumor-derived extracellular vesicle expressing a surface antigen, are provided. Provided are materials and methods for using the presence or absence of the biomarker to assess whether a subject should be treated with radiotherapy alone, or whether the subject would benefit from systemic therapy, either alone or in combination with radiotherapy.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 30/72 - Mass spectrometers
• A61P 35/00 - Antineoplastic agents

Abstract

Antibodies or portions thereof specific for human CCKBR, a composition comprising the antibody or portion thereof, an isolated cell expressing the antibody or portion thereof, and a method to inhibit or treat pain by using the antibody or portion thereof, are provided.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/22 - Anxiolytics
• A61P 25/24 - Antidepressants
• C12N 15/86 - Viral vectors

Abstract

This document provides methods and materials involved in treating cancer. For example, methods and materials for modulating (e.g., increasing or decreasing) an interleukin-1 (IL-1) signaling pathway (e.g., an IL-1βsignaling pathway) during an adoptive cell therapy (e.g., a chimeric antigen receptor (CAR) T cell therapy) are provided. In some cases, one or more inhibitors of an interleukin-1 receptor antagonist (IL-1RA) polypeptide can be used to increasing IL-1 signaling (e.g., to reduce immunosuppression of the administered cells). In some cases, CAR T cells having a reduced level of an interleukin 1 receptor, type I (IL-1R1) polypeptide can have decreased IL-1 signaling (e.g., to reduce T cell toxicity associated with the administered cells).

IPC Classes  ?

• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/42 - Cancer antigens
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Stemless components and fracture stems for joint arthroplasty, such as shoulder arthroplasty, are disclosed. Also, methods and devices are disclosed for the optimization of shoulder arthroplasty component design through the use of medical imaging data, such as computed tomography scan data.

IPC Classes  ?

• A61F 2/40 - Joints for shoulders
• A61F 2/30 - Joints
• B22F 10/20 - Direct sintering or melting
• B33Y 80/00 - Products made by additive manufacturing
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS

Abstract

A method and device for modulating the autonomic nervous system adjacent a pericardial space to treat cardiac arrhythmia includes a treatment source arranged to supply a treatment medium, a catheter having an end sized for insertion into the pericardial space, a medium delivery assembly having a distal end arranged to be positioned by the catheter into the pericardium, with the distal end of the delivery assembly comprising a delivery tip arranged to extend away from the distal end of the catheter into the pericardial space. A connector operatively couples the delivery tip of the medium delivery assembly to the treatment source, and the delivery tip of the medium delivery assembly including a plurality of delivery points for delivering the treatment medium at a plurality of treatment areas within the pericardial space. The device performs modulation or ablation of the autonomic nervous system at selected treatment areas within the pericardium.

IPC Classes  ?

• A61B 18/14 - Probes or electrodes therefor
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
• A61B 18/02 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
• A61B 18/12 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/20 - Applying electric currents by contact electrodes continuous direct currents
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

Provided herein is technology for breast cancer screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of breast cancer.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/6811 - Selection methods for production or design of target specific oligonucleotides or binding molecules
• C12Q 1/682 - Signal amplification
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
• C12Q 1/6853 - Nucleic acid amplification reactions using modified primers or templates
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

The present disclosure relates to methods and materials for assessing and/or treating obese mammals (e.g., obese humans). For example, methods and materials for using one or more interventions (e.g., individualized dietary interventions alone or in combination with pharmacological intervention(s)) to treat obesity and/or obesity-related comorbidities in a mammal (e.g., a human) identified as being likely to respond to a particular intervention (e.g., individualized dietary interventions alone or in combination with pharmacological intervention(s)) are provided.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 38/26 - Glucagons
• A61P 3/04 - AnorexiantsAntiobesity agents
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

Impending disruptive behavior in an individual is predicted using a machine learning model that processes measurement recorded with a wearable device. Measurement data are received from a wearable device and input to a trained machine learning model, generating predictive feature data as an output. The predictive feature data may include predictive scores, classifications, or the like, of a likelihood of a subject having a disruptive behavior.

IPC Classes  ?

• G08B 31/00 - Predictive alarm systems characterised by extrapolation or other computation using updated historic data
• G06N 20/20 - Ensemble learning
• G08B 21/02 - Alarms for ensuring the safety of persons

Abstract

A marker is localized using ultrasound imaging. Ultrasound video stream data are received with a computer system. The ultrasound video stream data are representative of ultrasound data acquired from a subject using an ultrasound system using Doppler imaging. Color image data are extracted from the ultrasound video stream data based on a color model. Marker position data are determined based on values of a color model component in the color image data. The marker position data are output using the computer system.

IPC Classes  ?

• G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• A61B 8/08 - Clinical applications
• G06T 7/90 - Determination of colour characteristics

Abstract

This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk of experiencing a major adverse cardiac event as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) are provided.

IPC Classes  ?

• A61K 38/19 - CytokinesLymphokinesInterferons
• A61K 38/18 - Growth factorsGrowth regulators
• A61K 38/45 - Transferases (2)
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 37/02 - Immunomodulators
• C07K 14/495 - Transforming growth factor [TGF]
• C07K 14/52 - CytokinesLymphokinesInterferons
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

This document provides methods and materials for reducing the risk of major adverse cardiac events. For example, methods and materials for identifying patients at risk of experiencing a major adverse cardiac evert as well as methods and material for treating patients at risk of experiencing a major adverse cardiac event (e.g., patients who underwent percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) are provided.

IPC Classes  ?

• A61K 38/19 - CytokinesLymphokinesInterferons
• A61K 38/18 - Growth factorsGrowth regulators
• A61K 38/45 - Transferases (2)
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 37/02 - Immunomodulators
• C07K 14/495 - Transforming growth factor [TGF]
• C07K 14/52 - CytokinesLymphokinesInterferons
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Methods for treating a human suffering from osteoarthritis are provided. Aspects of the methods include intra-articularly administering to the human a dosage comprising a nucleic acid coding sequence for a human interleukin-1 receptor antagonist (IL-1Ra) to treat the human suffering from osteoarthritis. Also provided are compositions for use in practicing the methods.

IPC Classes  ?

• A61K 38/20 - Interleukins
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• C12N 15/86 - Viral vectors

Abstract

Onset and/or continuation of a migraine attack is predicted in a subject using a machine learning model. Subject health data are accessed with a computer system, where the subject health data include clinical test or measurement data received from the subject and/or subject symptom data received from the subject. A trained machine learning model is accessed with the computer system, where the trained machine learning model has been trained on training data to predict a likelihood of migraine attack occurring within a specified timeframe based on features in subject health data. The subject health data are input to the trained machine learning model using the computer system, generating classified feature data as an output. The classified feature data indicate a likelihood of the subject having a migraine attack within the specified timeframe.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G06N 5/01 - Dynamic search techniquesHeuristicsDynamic treesBranch-and-bound
• G06N 20/20 - Ensemble learning

Abstract

e.ge.g., a human). For example, methods for using one or more lipase inhibitors to treat a mammal having or at risk of developing intestinal obstruction are provided.

IPC Classes  ?

• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/06 - Antihyperlipidemics
• A61K 31/365 - Lactones
• A61K 31/721 - Dextrans

Abstract

Described herein is a chin rest apparatus for a visual field system. The chin rest apparatus can include a base and at least one chin rest insert moveably coupled to the base and configured to be adjusted to one of a plurality of head turn angles and one of a plurality of head tilt angles. The plurality of head turn angles and plurality of head tilt angles can be associated with obtaining a visual field of a subject in the visual field system.

IPC Classes  ?

• A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
• A61B 3/024 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determining the visual field, e.g. perimeter types

Abstract

Electrical stimulation devices can be used to treat tinnitus. For example, tinnitus can be treated using implantable electrodes and stimulation devices for delivering electrical stimulation to a patient's cochlear region, such as the cochlear promontory. Intraosseous cochlear promontory electrode(s), endosteal electrode(s), subendosteal electrode(s), or short intracochlear electrode(s) (or a combination thereof), connected to a cochlear implant receiver/stimulator device, can provide a successful model for long-term treatment of tinnitus in a large number of patients. In some cases, patients can simply turn on the tinnitus implant when experiencing troublesome tinnitus and gain instant relief.

IPC Classes  ?

• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• H04R 25/00 - Deaf-aid sets

Abstract

This document relates to methods and materials for modulating (e.g., reducing) T cell activation (e.g., T cell proliferation, T cell effector functions, and/or cytokine secretion) using a TRAILshort polypeptide, a variant TRAILshort polypeptide, or a TRAILshort fusion polypeptide. For example, a TRAILshort polypeptide, a variant TRAILshort polypeptide, or a TRAILshort fusion polypeptide can be administered to a mammal in need thereof, e.g., a human with an autoimmune disorder, graft versus host disease, lichen planus or other disorder characterized by excessive T cell activation, to reduce excessive T cell activation (e.g., excessive T cell proliferation, excessive T cell effector functions, and/or excessive cytokine secretion).

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present disclosure provides methods for assessing and/or treating subjects having CCUS, MN, or AML. In some embodiments, treatment of a subject with TTKi prevents progression of TP53mutCCUS to TP53mutMN. In other embodiments, methods are provided to treat TP53mut MN with a TTKi, which functions by increasing genomic stability, increasing dysfunction of the spindle assembly checkpoint, and decreasing survival of aneuploidy cells. In another embodiment, the subject is treated with a TTKi in combination with at least one additional therapeutic agent, which may include a BCL-2 inhibitor, intensive chemotherapy, and a stem cell transplant.

IPC Classes  ?

• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61P 35/00 - Antineoplastic agents
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

This document provides methods and materials for treating cancer. For example, this document provides varicella-zoster viruses (VZVs; e.g., recombinant VZVs) having (e.g., designed to have) a genome that lacks at least a portion of one or more endogenous VZV nucleic acid sequences and methods for using such VZVs as an oncolytic agent (e.g., to treat cancer).

IPC Classes  ?

• A61K 35/768 - Oncolytic viruses not provided for in groups
• A61K 38/20 - Interleukins
• C07K 14/54 - Interleukins [IL]
• C12N 15/86 - Viral vectors
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 39/25 - Varicella-zoster virus
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants

Abstract

This document provides devices and methods for an automated tissue grossing system. For example, an automatic tissue grossing system can include an intake system configured to receive a specimen jar containing a tissue sample; a robotic arm comprising a gripper configured to grip the specimen jar; a decapping module comprising a stationary gripper configured to grip the specimen jar and a rotary gripper configured to rotate on a vertical axis and grip a lid of the specimen jar; and a vacuum module comprising an integrated grossing platform, wherein the grossing platform includes a slot sized to receive a cassette from the robotic arm and provide negative pressure through the slot to facilitate tissue transfer from the specimen jar to the cassette.

IPC Classes  ?

• G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
• G01N 35/04 - Details of the conveyor system
• G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations

Abstract

This document provides devices and methods for an automated tissue grossing system. For example, an automatic tissue grossing system can include an intake system configured to receive a specimen jar containing a tissue sample; a robotic arm comprising a gripper configured to grip the specimen jar; a decapping module comprising a stationary gripper configured to grip the specimen jar and a rotary gripper configured to rotate on a vertical axis and grip a lid of the specimen jar; and a vacuum module comprising an integrated grossing platform, wherein the grossing platform includes a slot sized to receive a cassette from the robotic arm and provide negative pressure through the slot to facilitate tissue transfer from the specimen jar to the cassette.

IPC Classes  ?

• G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
• G01N 1/28 - Preparing specimens for investigation
• G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations

Abstract

Provided are methods for inducing immune responses against pathogens in a mammal. The methods comprise administering a single cycle adenovirus (SC-Ad) comprising a nucleic acid sequence encoding an immunogen of said pathogen to said mammal. The SC-Ad is administered by inhalation and infects a cell of said mammal, thereby causing expression of said immunogen leading to the induction of said immune response. New infectious virions are not produced. The methods may be of particular utility in vaccination for respiratory pathogens. Corresponding medical uses of the SC-Ads are also provided.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses

Abstract

This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.

IPC Classes  ?

• C07D 295/192 - Radicals derived from carboxylic acids from aromatic carboxylic acids
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 211/64 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
• C07D 211/66 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
• C07D 213/64 - One oxygen atom attached in position 2 or 6
• C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Abstract

This document provides methods and materials for performing retinal pigment epithelium transplantation. For example, methods and materials for using fibrin supports for retinal pigment epithelium transplantation are provided.

IPC Classes  ?

• A61L 27/38 - Animal cells
• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• A61K 35/36 - SkinHairNailsSebaceous glandsCerumenEpidermisEpithelial cellsKeratinocytesLangerhans cellsEctodermal cells
• A61K 38/36 - Blood coagulation or fibrinolysis factors
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61L 27/22 - Polypeptides or derivatives thereof
• A61L 27/34 - Macromolecular materials
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61L 27/52 - Hydrogels or hydrocolloids
• C12N 5/079 - Neural cells

Abstract

A purified exosome product includes spherical or spheroid exosomes with a diameter no greater than 250 nm. In some embodiments, the purified exosome product has a moisture content of no more than 10%. The purified exosome product can be reconstituted to prepare an artificial blood product.

IPC Classes  ?

• A61K 9/50 - Microcapsules
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/16 - Blood plasmaBlood serum
• A61K 38/39 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

The present disclosure provides an anti-cancer lipid-based composition that kills very aggressive colorectal cancer cells. This composition is a concoction of an anti- cancer agent, 5-Fluorouracil and a glucocorticoid receptor (GR)-targeting cationic lipid delivery system, D1X. The uptake studies of these formulations have showed that formulations with dexamethasone enter into nucleus, bind GRE region and upregulate CYP3a5 gene. The intensity of upregulation is better than liposome without dexamethasone. Same results found in in vivo studies, the D1X5-FU shows better tumor regression and survivability than FOLFOX and FOLFIRI. The biodistribution studies showed that D1X5-FU targets only tumor tissues, not other organs. The pilot studies of tumor regression by other liposomal formulations- D1XLeucovorin, D1XOxaliplatin has showed better tumor regression than FOLFOX and FOLFIRI.

IPC Classes  ?

• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

A method for treating a subject having. or at risk of having. damaged endometrial tissue generally includes administering to the subject an amount of a PEP preparation effective to treat the subject's endometrial tissue. The PEP preparation may be administered therapeutically or prophylactically. In another aspect. a method of promoting proliferation of endometrial cells generally includes contacting the endometrial cells with an amount of a PEP preparation effective to promote proliferation of the endometrial cells. In another aspect. a method of promoting wound closure by endometrial cells generally includes administering to endometrial cells into which a wound has been introduced an amount of a PEP preparation effective to promote closure of the wound.

IPC Classes  ?

• A61K 35/19 - PlateletsMegacaryocytes
• A61P 15/02 - Drugs for genital or sexual disordersContraceptives for disorders of the vagina

Abstract

A system obtains a maternal electrocardiogram (ECG) signal that represents an ECG of a pregnant mother during a first time interval. The system further obtains a mixed maternal-fetal ECG signal that represents a combined ECG of the mother and her fetus during the first time interval; processes the maternal ECG signal and the mixed maternal-fetal ECG signal to generate a fetal ECG signal that represents the ECG of the fetus during the time interval, the fetal ECG signal substantially excluding the maternal ECG signal; and provides an output based on the fetal ECG signal.

IPC Classes  ?

• A61B 5/344 - Foetal cardiography
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/024 - Measuring pulse rate or heart rate
• A61B 5/332 - Portable devices specially adapted therefor
• A61B 5/339 - Displays specially adapted therefor
• A61B 5/349 - Detecting specific parameters of the electrocardiograph cycle

Abstract

This document describes devices and methods for providing stereotactic navigation during surgical procedures. For example, this document describes devices and methods for providing stereotactic navigation using fiducial markers to align medical imaging data with a patient's anatomy. Further, this document describes a stereotactic navigation system comprising a dental prosthesis sized to fit a maxillary dental pattern of a patient, a set of fiducial markers located on the dental prosthesis, wherein the dental prosthesis is configured to be attached to maxillary teeth of the patient.

IPC Classes  ?

• A61B 90/16 - Bite blocks
• A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis

Goods & Services

Medical research laboratory services; Medical research; Medical and scientific research, namely, conducting clinical trials for others; Providing on-line non-downloadable software for reviewing, rating, and ranking patient quality outcomes, patient experience, patient safety, healthcare services, hospital services, and healthcare facilities

Goods & Services

Providing information, reviews, ratings, and rankings in the fields of patient quality outcomes, patient experience, patient safety, healthcare, hospital services, and healthcare facilities; Providing an on-line searchable database featuring information, reviews, ratings, and rankings in the fields of patient quality outcomes, patient experience, patient safety, healthcare, hospital services, and healthcare facilities; Medical services; Healthcare services

Goods & Services

Publication of on-line materials in the field of hospitals, hospital rankings, healthcare, and medical care; Arranging and conducting of educational seminars in the field of hospitals, healthcare, and medical care; Virtual training services in the field of hospitals, healthcare, and medical care

Abstract

Described herein are systems, methods, and apparatuses for identifying LQTS in a subject. A system may include an electrocardiogram (ECG) sensor configured to detect an ECG datum. A system may include a computing device configured to receive an electrocardiogram (ECG) datum; train an LQTS determination machine learning model on a training dataset including a plurality of example ECG data as inputs correlated to a plurality of example LQTS data as outputs; and generate an LQTS determination datum as a function of the ECG datum using the trained LQTS determination machine learning model. A system may include a display configured to display an LQTS determination datum.

IPC Classes  ?

• G06N 3/08 - Learning methods
• G06N 3/0464 - Convolutional networks [CNN, ConvNet]

Abstract

This document provides devices and methods for the treatment of heart conditions, hypertension, and other medical disorders. For example, this document provides devices and methods for treating atrial fibrillation by performing thoracic vein ablation and/or electroporation procedures, including pulmonary vein myocardium ablation. In some embodiments, the ablation and/or electroporation is delivered in differing areas in and/or around the pulmonary vein in coordination with each other for enhanced efficacy.

IPC Classes  ?

• A61B 18/14 - Probes or electrodes therefor
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body

Abstract

An apparatus and method for training an artificial intelligence-supported diagnostic assessment tool may provide rapid and accurate prognosis determinations. Apparatus may include at least a processor configured to receive a plurality of multi-channel sensor readings of physiological data, generate training data correlating each of the plurality of multi-channel sensor readings with a plurality of diagnostic labels, train a neural network using the plurality of diagnostic labels, receive a time series input describing user physiological data from at least a sensor, input the time series input into the trained neural network, generate diagnostic data as a function of the time series input and the trained neural network, determine prognostic data as a function of the diagnostic data, and output the prognostic data.

IPC Classes  ?

• G06N 3/0464 - Convolutional networks [CNN, ConvNet]
• A61B 5/349 - Detecting specific parameters of the electrocardiograph cycle
• A61B 8/08 - Clinical applications
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

This disclosure provides methods and compositions for lowering blood pressure in a patient in need thereof. This disclosure also provides methods and compositions for sustained lowering of blood pressure in a patient in need thereof. The methods provided therein may be used in combination with one or more antihypertensive drugs or diuretics.

IPC Classes  ?

• A61K 38/22 - Hormones
• C07K 14/58 - Atrial natriuretic factor complexAtriopeptinAtrial natriuretic peptide [ANP]CardionatrinCardiodilatin
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• C07K 14/575 - Hormones

Abstract

This document provides methods and materials for delivering vectors (e.g., non-viral vectors or viral vectors such as adeno-associated viral (AAV) vectors) to localized areas within a mammal (e.g., a human). For example, a fibrin hydrogel including vectors (e.g., non-viral vectors or viral vectors such as AAV vectors) can be administered directly to the retina of an eye within a mammal (e.g., a human) to deliver the vectors to the retina.

IPC Classes  ?

• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/58 - Materials at least partially resorbable by the body
• C12N 15/86 - Viral vectors
• A61L 27/38 - Animal cells

Abstract

This document provides methods and materials involved in treating cancer. For example, methods and materials for using (a) one or more antibody-drug conjugates (ADCs) and (b) one or more proteolysis-targeting chimera (PROTAC) compounds to treat a mammal (e.g., a human) having cancer are provided.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• C07K 19/00 - Hybrid peptides
• A61P 35/00 - Antineoplastic agents

Abstract

Three-dimensional (3D) medical images are generated from two-dimensional (2D) medical images using a vision transformer-based machine learning model. 2D image data is accessed with a computer system. The 2D image data may include 2D kV images acquired from a subject while the subject is positioned at a treatment position of a radiation treatment system. A machine learning model trained on training data to reconstruct 3D medical images from 2D medical images is accessed with the computer system. The 2D image data is input to the machine learning model using the computer system, generating 3D image data as an output. The 3D image data may then be output via the computer system.

IPC Classes  ?

• G06T 17/00 - 3D modelling for computer graphics

Abstract

This document provides methods and materials for assessing cancer. For example, methods and materials that can be used to determine if a mammal (e.g., a human) having cancer is likely to be responsive to a cancer immunotherapy (e.g., a chimeric T cell therapy) are provided. In some cases, methods and materials for treating a mammal having cancer and identified as being likely to respond to a cancer immunotherapy (e.g., a chimeric T cell therapy) are also provided.

IPC Classes  ?

• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 31/325 - Carbamic acidsThiocarbamic acidsAnhydrides or salts thereof
• A61K 31/336 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
• A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/02 - Antineoplastic agents specific for leukemia

Abstract

Provided herein is technology for esophageal disorder screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of esophageal disorders (e.g., Barrett's esophagus, Barrett's esophageal dysplasia, etc.). In addition, the technology provides methods, compositions and related uses for distinguishing between Barrett's esophagus and Barrett's esophageal dysplasia, and between Barrett's esophageal low-grade dysplasia, Barrett's esophageal high-grade dysplasia, and esophageal adenocarcinoma within samples obtained through endoscopic brushing or nonendoscopic whole esophageal brushing or swabbing using a tethered device (e.g. such as a capsule sponge, balloon, or other device).

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present disclosure provides compositions and methods related to the detection of coccidioidomycosis (Valley fever). In particular, the present disclosure provides novel compositions and methods related to the detection and/or quantification of coccidioidomycosis in a subject using an enzyme-linked immunoassay (ELISA) that measures coccidioidal CTS1 antigen and/or anti-CTS1 antibodies in human serum.

IPC Classes  ?

• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

Tissue markers may be implanted percutaneously through a needle into soft tissue to locate a site of a procedure at a later date. A medical implantation device for percutaneously implanting a tissue marker can include a housing extending from a proximal end to a distal end. The device may also include an obturator coupler disposed at the distal end of the housing to couple an obturator to the housing, and a guide track extending from a first track opening disposed at a distal end of the track toward a proximal end of the housing. The device can further include an actuator to be received within the guide track, where the actuator includes a cannula coupler disposed at a distal end of the actuator to couple a cannula to the actuator. The device can also include a latch arm configured to lock a position of the actuator along the guide track.

IPC Classes  ?

• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

A trans-illuminating needle guide device for guiding a needle into and illuminating an arteriovenous (AV) fistula in a subject includes: a housing comprising a base, a needle guide insert having a pair of opposing side walls defining a first angled slot, a second angled slot, and a plurality of grooves, a needle guide having a guide channel configured to receive the needle, a first deflectable plate configured to be received by the first angled slot and the plurality of grooves, and a second deflectable plate configured to be received by the second angled slot, a first plurality of light emitting diodes (LEDs) disposed within the housing and configured to emit light of a first wavelength, and a second plurality of LEDs disposed within the housing and configured to emit light of a second wavelength, the second wavelength differing from the first wavelength.

IPC Classes  ?

• A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
• A61B 17/34 - TrocarsPuncturing needles
• A61M 5/42 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced

Abstract

We have developed novel shear-thinning biomaterials using silica nanoparticles, gelatin-based polymers and small molecules such as doxorubicin. Shear-thinning biomaterial technology offers enables polymers and drugs loaded inside such polymers to be easily delivered directly through catheters into target area for use, for example, in cancer therapy and immunotherapy. When a force above a certain threshold is applied to inject such materials, they “thin” and behaves as a semi-solid, allowing the material to readily flow through a catheter. When the force is removed, the material instantly becomes a soft solid with significant cohesive properties that prevent it from dislodging or breaking up.

IPC Classes  ?

• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 9/06 - OintmentsBases therefor
• A61K 9/51 - Nanocapsules
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 35/00 - Antineoplastic agents

Abstract

This document provides method and materials for treating cancer. In some cases, methods and materials for treating estrogen receptor negative (ER-) cancers (e.g., ER- breast cancers such as triple-negative breast cancers (TNBCs)) are provided. For example, one or more endoxifen (ENDX) compounds can be administered to a mammal (e.g., a human) having an ER- cancer (e.g., an ER- breast cancer such as a TNBC) to treat that mammal. For example, one or more ENDX compounds and one or more agents/therapies that can alter the antigens presented on the surface of a cancer cell can be administered to a mammal (e.g., a human) having an ER+ cancer and/or an ER- cancer (e.g., an ER- breast cancer such as a TNBC) to treat that mammal.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61P 35/00 - Antineoplastic agents

Abstract

Motion correction in ultrasound imaging uses a suitably trained machine learning algorithm or model to correct for tissue motion in ultrasound images. A reference frame is selected from the input image data to use as a ground truth input to the machine learning model.

IPC Classes  ?

• G06T 7/20 - Analysis of motion
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• G06T 5/50 - Image enhancement or restoration using two or more images, e.g. averaging or subtraction
• G06T 5/60 - Image enhancement or restoration using machine learning, e.g. neural networks
• G06T 5/73 - DeblurringSharpening

Abstract

Computed tomography (CT) images obtained using an energy-integrating detector (EID) are enhanced by increasing their spatial resolution, reducing noise, and/or reducing artifacts. The enhanced CT image data are generated by inputting the EID-CT image data to a suitably trained machine learning model, such as a neural network. The machine learning model is trained on training data that includes CT image pairs. Each CT image pair includes a high-resolution photon-counting detector CT (PCD-CT) image and a low-resolution CT image, which may be an EID-CT image, noise information from an EID-CT image, or a degraded PCD-CT image.

IPC Classes  ?

• G06T 11/00 - 2D [Two Dimensional] image generation
• G06T 3/4053 - Scaling of whole images or parts thereof, e.g. expanding or contracting based on super-resolution, i.e. the output image resolution being higher than the sensor resolution
• G06T 5/60 - Image enhancement or restoration using machine learning, e.g. neural networks

Abstract

Systems and methods for fact checking large language model outputs include inputting data to a first trained large language machine learning model at a foundation layer to generate vectorized data; submitting a retrieval query to the trained large language machine learning model and encoding the retrieval query with a structure corresponding to the vectorized data; performing a semantic search for matches between the vectorized data and the retrieval query; inputting the retrieval query and matches of the semantic search to the trained large language machine learning model; generating, at the trained large language machine learning model, a summary; determining, at the trained large language machine learning model, one or more parts of the summary for fact checking by a user; inputting the parts of the summary for fact checking into the large language machine learning model to retrieve references associated with the summary; and displaying the summary and the references.

IPC Classes  ?

• G06F 11/36 - Prevention of errors by analysis, debugging or testing of software
• G06F 16/33 - Querying
• G06F 40/226 - Validation
• G06F 40/30 - Semantic analysis
• G06N 3/0475 - Generative networks

Abstract

Systems and methods for fact checking large language model outputs include inputting data to a first trained large language machine learning model at a foundation layer to generate vectorized data; submitting a retrieval query to the trained large language machine learning model and encoding the retrieval query with a structure corresponding to the vectorized data; performing a semantic search for matches between the vectorized data and the retrieval query; inputting the retrieval query and matches of the semantic search to the trained large language machine learning model; generating, at the trained large language machine learning model, a summary; determining, at the trained large language machine learning model, one or more parts of the summary for fact checking by a user; inputting the parts of the summary for fact checking into the large language machine learning model to retrieve references associated with the summary; and displaying the summary and the references.

IPC Classes  ?

• G06N 20/00 - Machine learning
• G06F 40/226 - Validation
• G06F 11/36 - Prevention of errors by analysis, debugging or testing of software
• G06F 40/30 - Semantic analysis
• G06F 40/40 - Processing or translation of natural language
• G06F 16/33 - Querying
• G06N 3/0455 - Auto-encoder networksEncoder-decoder networks
• G06F 11/07 - Responding to the occurrence of a fault, e.g. fault tolerance
• G06Q 10/06 - Resources, workflows, human or project managementEnterprise or organisation planningEnterprise or organisation modelling

Abstract

Described here are systems and methods for magnetic resonance imaging using motion encoding gradients that are shaped based on one or more basis functions of an integral transform. These motion encoding gradients are capable of encoding broadband tissue motion. The motion encoding gradients can implement multiple scales, shapes, or variations of one or more basis functions, series, or systems to facilitate encoding and detecting broadband tissue motion. The underlying tissue motion can be decoded using an inverse transform corresponding to the inverse of the integral transform on which the one or more basis functions are based.

IPC Classes  ?

• G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques

Abstract

This document provides methods and materials related to using infectious nucleic acid encoding viruses to reduce the number of viable cancer cells within a mammal. For example, methods for using infectious nucleic acid to treat cancer, engineered viral nucleic acid, and methods for making engineered viral nucleic acid are provided.

IPC Classes  ?

• A61K 35/76 - VirusesSubviral particlesBacteriophages
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

A suture-carrying apparatus includes a suture engaging ridge for placement and retention of surgical sutures, and a base for conveniently mounting the apparatus to a predetermined location, such as a body structure, which is reachable by robotic arms during a robot-assisted surgical operation. The base may be configured to allow stability of the apparatus for one-handed placement and retrieval of sutures from the ridges.

IPC Classes  ?

• A61B 17/06 - NeedlesHolders or packages for needles or suture materials
• A61B 17/30 - Surgical pincettes, i.e. surgical tweezers
• A61B 34/30 - Surgical robots
• A61B 90/92 - Identification means for patients or instruments, e.g. tags coded with colour

Abstract

This document provides methods and materials involved in treating a mammal (e.g., a human) having (or risk of developing) graft-versus-host disease (GVHD). For example, T cells (e.g., regulatory T cells) expressing one or more antigen receptors targeting one or more epithelial-specific antigens are provided. Also provided are methods for administering T-cells expressing one or more antigen receptors targeting one or more epithelial-specific antigens to a mammal having (or at risk of developing) GVHD to treat the GVHD.

IPC Classes  ?

• C07K 14/725 - T-cell receptors
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/22 - Immunosuppressive or immunotolerising
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/41 - Vertebrate antigens
• A61K 40/42 - Cancer antigens
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

An illumination system includes an array of LEDs including a plurality of first LEDs and a plurality of second LEDs. A microlens array overlays the plurality of LEDs and includes a plurality of first lenses corresponding to the plurality of first LEDs and a plurality of second lenses corresponding to the plurality of second LEDs. A first geometry of at least one of the plurality of first lenses is different than a second geometry of at least one of the plurality of second lenses. An imaging device is configured to capture an image based on light reflected from the array of LEDs. At least one processing device is in communication with the array of LEDs and the imaging device. The at least one processing device is configured to identify a shadow cast on the target region by an obstruction and selectively activate the array of LEDs based on the shadow.

IPC Classes  ?

• F21V 5/00 - Refractors for light sources
• F21K 9/233 - Retrofit light sources for lighting devices with a single fitting for each light source, e.g. for substitution of incandescent lamps with bayonet or threaded fittings specially adapted for generating a spot light distribution, e.g. for substitution of reflector lamps
• F21V 21/03 - Ceiling bases, e.g. ceiling roses
• F21V 21/26 - Pivoted arms
• F21W 131/20 - Lighting for medical use
• F21Y 105/18 - Planar light sources comprising a two-dimensional array of point-like light-generating elements characterised by the overall shape of the two-dimensional array annularPlanar light sources comprising a two-dimensional array of point-like light-generating elements characterised by the overall shape of the two-dimensional array polygonal other than square or rectangular, e.g. for spotlights or for generating an axially symmetrical light beam
• F21Y 115/10 - Light-emitting diodes [LED]
• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer

Abstract

A surgical clip includes one or more ring-shaped premagnetized weights received by a tubular body structure or by an actuatable grasping element (e.g., microforceps, a clamp, or the like). A system and method for manipulating tissue during a surgical procedure uses at least one surgical clip that is affixed to tissue within an animal body and is configured to be delivered with an endoscope or similar surgical device. A magnetic field source external to the animal body is moved using at least one robotic actuator and generates magnetic field(s) used to alter position of surgical clip(s) affixed to tissue. A surgical clip includes a tubular body structure, a grasping element, and internal elements (e.g., including a grasping element actuating mechanism), with the ring-shaped premagnetized weights being configured to cooperate with an external end effector to permit manipulation of tissue when grasped by the grasping element.

IPC Classes  ?

• A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
• A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor

Abstract

An apparatus and method for determining positional information of a steerable assembly within an animal body utilizing a plurality of fiber bragg grating (FBG) sensors arranged along a length of an elongated fiber. A polymeric tube having a sealed end contains the elongated fiber and FBG sensors to form a sheathed FBG sensor assembly. A reference point of the elongated fiber is fixable to an external support structure, and a portion of the assembly is insertable through a passage defined by the steerable assembly within the body. A method includes fixing the reference point of the elongated fiber, inserting the sheathed sensor assembly into a passage of the steerable assembly, and recording a configuration of the elongated fiber utilizing the FBG sensors.

IPC Classes  ?

• A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
• A61B 10/04 - Endoscopic instruments, e.g. catheter-type instruments
• G02B 23/24 - Instruments for viewing the inside of hollow bodies, e.g. fibrescopes
• A61B 1/0005 -

Abstract

Systems and methods for analyzing multimodal data using one or more large language machine learning models may include inputting medical image data to a trained image-based machine learning model and generating medical image data embeddings; inputting genomic data to a trained genomics machine learning model and generating genomic data embeddings; inputting text data to a trained large language machine learning model, and generating a mapping of extruded data; and feeding the medical image data embeddings, the genomic data embeddings, and the mapping of extruded data to trained large language machine learning model at a foundation layer, the trained large language machine learning model at the foundation layer being trained to generate one or more of a data and analytics report, a diagnostic analysis report, a large language model agent, or user data for display in a user interface at an output device.

IPC Classes  ?

• G16H 10/00 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data
• G06N 3/0455 - Auto-encoder networksEncoder-decoder networks
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G06N 3/02 - Neural networks
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G06N 20/00 - Machine learning
• G06F 40/20 - Natural language analysis
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G06N 3/08 - Learning methods
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

Devices, systems, and methods described in this disclosure can be used to deliver electroporation to treat enlarged turbinate's and/or chronic sinusitis via the usage of electrical energy. For example, this document describes devices, systems, and methods for delivering thermal or non-thermal electroporation to treat enlarged turbinates and chronic sinusitis. Such an electroporation delivery device may optionally include one or more of the following features. The balloon may be made of a porous material. The one or more electrode spines may include four electrode spines. The one or more electrodes may include at least four electrodes. The balloon may be an elliptical, frustoconical, or conical shape when inflated. The electroporation therapy devices, systems, and methods described herein address limitations related to the current techniques for turbinate reduction (i.e., electrocautery, cryosurgery, or surgical reduction).

IPC Classes  ?

• A61B 18/14 - Probes or electrodes therefor
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body

Abstract

A guidance device is provided. The guidance device may include a fastener, a panel including a first surface, a second surface opposite the first surface, and a plurality of holes formed on the first surface and configured to receive the fastener. The plurality of holes may include a first hole and a second hole. The fastener may be configured to pass through the first hole and the second hole, and form a loop. The loop formed by the fastener may be configured to receive a medical device between the fastener and the first surface of the panel. A size of the loop may be adjustable to receive the medical device and secure the medical device.

IPC Classes  ?

• A61B 17/34 - TrocarsPuncturing needles

Abstract

This document relates to methods and materials for treating cancer. For example, this document provides methods and materials for using one or more signal transducer and activator of transcription 3 (STAT3) polypeptide inhibitors to treat a mammal (e.g., a human) having cancer (e.g., a brain cancer such as a glioma).

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/415 - 1,2-Diazoles
• A61K 31/33 - Heterocyclic compounds
• A61K 31/19 - Carboxylic acids, e.g. valproic acid

Abstract

Systems and methods for providing hypothesis-driven artificial intelligence (HD-AI), such as, for oncology research. One method may include receiving a request to perform a disease analysis. The method may include performing the requested disease analysis using a HD-AI model trained using domain knowledge and one or more hypotheses. The method may include generating and transmitting a report based on the disease analysis, where the report may include mechanistic explanation or interpretation of the result of the disease analysis.

IPC Classes  ?

• G06N 5/022 - Knowledge engineeringKnowledge acquisition
• G06N 20/00 - Machine learning
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present invention biomaterial-based composite ink formulations for use in endoscopic imaging (including in colon tattooing) procedures and their methods of production. The biomaterial-based composite ink formulations comprise at least one contrast agent selected from the group consisting of: iron oxide, copper oxide, carbon nanotube, and graphene oxide; and at least one polysaccharide-based biomaterial selected from chitosan or its derivative. The contrast agents are preferably nanoparticles.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges

Abstract

A physical system receives and records measurements from a plurality of sensors for the physical system over a period of time and creates therefrom a statistical model of normal behavior of the physical system. The statistical model is applied to monitor the physical system for events or significant changes. The method detects events or significant changes in the operation or behavior of the physical system responsive to the monitoring of the physical system for events or significant changes. Events or significant changes in the operation or behavior of the physical system may cause a notification or alert, which can be sent a supervisory system.

IPC Classes  ?

• G05B 23/02 - Electric testing or monitoring
• G06F 11/30 - Monitoring
• G06F 11/34 - Recording or statistical evaluation of computer activity, e.g. of down time, of input/output operation

Abstract

Systems and methods for performing motion artifact correction in medical images. One method includes receiving, with an electronic processor, a medical image associated with a patient, the medical image including at least one motion artifact. The method also includes applying, with the electronic processor, a model developed using machine learning to the medical image for correcting motion artifacts, the model including at least one of a spatial transformer network and an attention mechanism network. The method also includes generating, with the electronic processor, a new version of the medical image, where the new version of the medical image at least partially corrects the at least one motion artifact.

IPC Classes  ?

• G06T 5/73 - DeblurringSharpening
• G06T 5/50 - Image enhancement or restoration using two or more images, e.g. averaging or subtraction
• G06T 5/60 - Image enhancement or restoration using machine learning, e.g. neural networks

Abstract

According to aspects disclosed herein, an infusion lead assembly may include a housing including a needle receptacle, a housing lumen, a pin receptacle, and a housing conductive trace; a connector including an connector needle, an internal lumen, a metal pin, and a connector conductive trace, and an infusion lead body including an infusion lumen, an exit port, an internal wire, and a distal electrode. The infusion lead assembly may form an electrical path to transmit electrical signals across the connector conductive trace, the metal pin, the housing conductive trace, the internal wire, and the distal electrode. The infusion lead assembly may form a fluid path to transmit fluid across the internal lumen, the connector needle, the infusion lumen, and the exit port.

IPC Classes  ?

• A61M 19/00 - Devices for local anaesthesiaDevices for hypothermia
• A61M 5/14 - Infusion devices, e.g. infusing by gravityBlood infusionAccessories therefor
• A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
• A61M 39/02 - Access sites
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

This specification discloses systems, methods, and techniques for classifying a grade of cancer represented in a tumor tissue sample. The techniques include obtaining a whole-slide image (WSI) of the tumor tissue sample and partitioning the WSI into a collection of patches. For each patch, (i) a contextualized feature representation of the patch is generated based on intrinsic features of the patch, local dependencies between the patch and a subset of local patches of the WSI, and non-local dependencies between the patch and a subset of non-local patches of the WSI; and (ii) an attention weight is determined for the patch. A WSI-level cancer grade for the tumor tissue sample is predicted based on the contextualized feature representations and the attention weights for the plurality of patches.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06N 5/04 - Inference or reasoning models
• G06N 3/08 - Learning methods
• G06T 7/11 - Region-based segmentation
• G06T 7/246 - Analysis of motion using feature-based methods, e.g. the tracking of corners or segments
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G06N 20/00 - Machine learning
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS

Abstract

Disclosed herein are techniques for deidentifying personally identifiable information (Pll). A method includes training a large language model (LLM) on a set of clinical records to generate a clinical analysis; fine tuning the LLM on a set of Pll training data to identify Pll using machine learning-based name entity recognition; receiving from a client device a clinical analysis request and a patient identifier; providing, to the LLM the clinical analysis request and one or more patient records associated with the patient identifier, causing the LLM to generate a clinical analysis, identify one or more Pll instances in the clinical analysis, deidentify at least one of the one or more Pll instances to generate a deidentified clinical analysis; receiving from the LLM a deidentified clinical analysis; and transmitting the deidentified clinical analysis to the client device.

IPC Classes  ?

• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G06F 21/62 - Protecting access to data via a platform, e.g. using keys or access control rules

Abstract

A computer-implemented method comprising receiving, via one or more processors, an input query associated with a patient; obtaining, via one or more processors, a healthcare record associated with the patient; analyzing, via the one or more processors and using a trained machine learning model, the healthcare record associated with the patient to extract data elements relevant to the input query; and generating, via the one or more processors and using the trained machine learning model, a first mapping of the extracted data elements relevant to the query.

IPC Classes  ?

• G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

Systems and methods provide a novel computational approach to planning the endovascular treatment of cardiovascular diseases. In particular, the invention simulates medical device deployment and hemodynamic outcomes using a virtual patient-specific anatomical model of the area to be treated, high-fidelity finite element medical device models and computational fluid dynamics (CFD). In an embodiment, the described approach investigates the effects of coil packing density, coil shape, aneurysmal neck size and parent vessel flow rate on aneurysmal hemodynamics. A processor may receive patient clinical data used to construct the relevant anatomical structure model. The processor may access medical device models constructed using finite element analysis and three dimensional beam analysis, and simulates the deployment of selected medical devices in the anatomical structure model. The selected medical device models and the anatomical structure model mesh, allowing the processor to simulate hemodynamic outcomes using computational fluid dynamics.

IPC Classes  ?

• G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine
• G09B 5/02 - Electrically-operated educational appliances with visual presentation of the material to be studied, e.g. using film strip

Abstract

Techniques for optimizing summary generation using generative artificial intelligence (Al) models are disclosed herein. An example computing system comprises: one or more processors; and one or more memories. The one or more memories have stored thereon computer-executable instructions that, when executed by the one or more processors, cause the computing system to: receive an input from a provider, the input including first data associated with a user; generate, by executing a trained machine learning (ML) model, an output including a history of present illness (HPI) summary by: identifying a subspeciality of the provider, aggregating (i) a prior input including second data associated with the user and (ii) a test value corresponding to the prior input, and determining the output based on the input, the subspeciality of the provider, the prior input, and the test value; and cause the HPI summary to be displayed at a device.

IPC Classes  ?

• G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof

Abstract

Uncertainty assessment of medical image noise reduction includes quantifying and visualizing the pixel-wise uncertainty, in the form of dispersion and bias, attributable to a convolutional neural network (“CNN”), other deep learning, machine learning, or other artificial intelligence-based noise reduction techniques. An uncertainty map that quantifies or otherwise depicts the spatial distribution of un-certainty in a processed medical image is generated using a bootstrap approximation and/or a trained machine learning algorithm. These uncertainty maps provide a confidence map on the information at different locations, organs, tissues, and/or findings in the medical images, thereby providing clinicians with additional information otherwise not available to them for making decisions about or based on the content of the medical images.

IPC Classes  ?

• G06T 5/70 - DenoisingSmoothing
• G06T 5/60 - Image enhancement or restoration using machine learning, e.g. neural networks
• G06T 11/00 - 2D [Two Dimensional] image generation
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing

Abstract

The present application provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions are also provided and are useful for treating and/or preventing heart failure, obesity, type 2 diabetes mellitus, hypertension, functional dyspepsia, cholestasis, and non-alcoholic fatty liver disease.

IPC Classes  ?

• C07D 285/135 - Nitrogen atoms
• A61K 31/433 - Thiadiazoles
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

This document relates to methods and materials for treating pancreatitis (e.g., chronic pancreatitis) in a mammal (e.g., a human). For example, methods for using one or more lipase inhibitors to treat a mammal having or at risk of developing pancreatitis (e.g., chronic pancreatitis) are provided.

IPC Classes  ?

• A61K 31/365 - Lactones
• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes

Abstract

This document describes methods and materials for improving the delivery of electroporation. For example, this document describes methods and devices for delivering electroporation while mitigating risks of ventricular fibrillation.

IPC Classes  ?

• A61N 1/365 - Heart stimulators controlled by a physiological parameter, e.g. by heart potential
• A61B 5/283 - Invasive
• A61B 5/316 - Modalities, i.e. specific diagnostic methods
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
• A61B 18/12 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/32 - Applying electric currents by contact electrodes alternating or intermittent currents

Goods & Services

Downloadable software for managing, creating, and analyzing electronic medical records, transcribing audio to written text, and for recording and transcribing patient interactions; Downloadable computer software using artificial intelligence (AI) for managing, creating, and analyzing electronic medical records, transcribing audio to written text, and for recording and transcribing patient interactions; Downloadable printable educational materials in the field of nursing and medical care

Goods & Services

Arranging and conducting of educational seminars in the field of nursing and medical care; Virtual training services in the field of nursing and medical care; Publication of on-line materials in the field of nursing and medical care